Research programme: anti CD44v6 CAR transduced T-cells - MolMed/San Raffaele Hospital

Drug Profile

Research programme: anti CD44v6 CAR transduced T-cells - MolMed/San Raffaele Hospital

Alternative Names: CAR-CD44v6 immune gene therapy - MolMed; CARCD44v6; Chimeric antigen receptor CD44v6 immune gene therapy - MolMed

Latest Information Update: 19 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scientific Institute San Raffaele
  • Class CAR-T cell therapies; Gene therapies
  • Mechanism of Action CD44 antigen inhibitors; Cytotoxic T lymphocyte stimulants; Gene transference; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 13 Apr 2015 MolMed exercises its option right to acquire CAR-CD44v6 project from San Raffaele Hospital (OSR)
  • 13 Apr 2015 Preclinical trials in Haematological malignancies in Italy (Parenteral)
  • 13 Apr 2015 Preclinical trials in Solid tumours in Italy (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top